Among individuals with overweight or obesity, third-quartile dosing was not associated with increased PPH risk.<h4>Conclusion</h4>Elevated BMI was associated with greater oxytocin requirements, but risks associated with increased dosing were attenuated in individuals with higher BMI. This evidence concerns the gene OXT and obesity disorder.